Jerusalem Pharmaceuticals Co. Ltd. (PEX:JPH)
Palestine · Delayed Price · Currency is JOD · Price in USD 4.640
+0.040 (0.87%)
At close: Feb 11, 2026
Jerusalem Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 47.15 | 39.82 | 39.65 | 46.14 | 46.23 | 36.4 | |
Revenue Growth (YoY) | 25.91% | 0.42% | -14.06% | -0.18% | 27.00% | 6.77% |
Cost of Revenue | 21.94 | 19.7 | 18.31 | 23 | 23.44 | 20.28 |
Gross Profit | 25.21 | 20.12 | 21.34 | 23.14 | 22.79 | 16.12 |
Selling, General & Admin | 11.65 | 10.52 | 10.77 | 12.23 | 12.57 | 10.4 |
Research & Development | 1.07 | 1.12 | 0.93 | 1.73 | 1.74 | 1.38 |
Other Operating Expenses | 0.5 | -0.09 | -0.15 | -0.26 | 0.07 | 0.11 |
Operating Expenses | 14.03 | 13.42 | 12.36 | 14.33 | 14.81 | 12.11 |
Operating Income | 11.18 | 6.7 | 8.98 | 8.81 | 7.98 | 4.01 |
Interest Expense | - | -0.02 | -0.04 | -0.06 | -0.06 | -0.06 |
Interest & Investment Income | 0.01 | - | - | 0.03 | 0.02 | 0.05 |
Earnings From Equity Investments | - | - | - | - | -0 | 0.02 |
Currency Exchange Gain (Loss) | -0.62 | -0.64 | -0.08 | 0.36 | -0.21 | -0.07 |
Other Non Operating Income (Expenses) | -0.29 | -0.29 | -0.19 | -0.14 | -0.16 | -0.22 |
EBT Excluding Unusual Items | 10.28 | 5.76 | 8.68 | 9 | 7.57 | 3.74 |
Gain (Loss) on Sale of Investments | 1.71 | 0.84 | 0.04 | 0 | 0 | 0 |
Gain (Loss) on Sale of Assets | 0 | 0 | 0.11 | - | 0.01 | - |
Other Unusual Items | 0.02 | 0.02 | - | 0.03 | 0.04 | 0 |
Pretax Income | 12.02 | 6.62 | 8.82 | 9.03 | 7.62 | 3.74 |
Income Tax Expense | 2.12 | 1.56 | 1.81 | 1.82 | 1.4 | 0.07 |
Earnings From Continuing Operations | 9.89 | 5.06 | 7.01 | 7.21 | 6.22 | 3.67 |
Earnings From Discontinued Operations | - | - | - | -0.21 | - | - |
Net Income to Company | 9.89 | 5.06 | 7.01 | 7 | 6.22 | 3.67 |
Minority Interest in Earnings | -0.05 | -0.02 | -0.05 | 0.17 | 0.38 | 0.06 |
Net Income | 9.85 | 5.04 | 6.96 | 7.17 | 6.6 | 3.73 |
Net Income to Common | 9.85 | 5.04 | 6.96 | 7.17 | 6.6 | 3.73 |
Net Income Growth | 139.49% | -27.58% | -3.02% | 8.73% | 77.11% | -30.39% |
Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 | 18 |
Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 | 18 |
Shares Change (YoY) | 0.23% | - | - | - | - | - |
EPS (Basic) | 0.55 | 0.28 | 0.39 | 0.40 | 0.37 | 0.21 |
EPS (Diluted) | 0.55 | 0.28 | 0.39 | 0.40 | 0.37 | 0.21 |
EPS Growth | 138.94% | -27.58% | -3.02% | 8.73% | 77.11% | -30.39% |
Free Cash Flow | 3.87 | 9.94 | 7.84 | 16.32 | 3.86 | 0.45 |
Free Cash Flow Per Share | 0.21 | 0.55 | 0.44 | 0.91 | 0.21 | 0.03 |
Dividend Per Share | 0.080 | 0.080 | 0.100 | 0.150 | 0.120 | 0.080 |
Dividend Growth | -20.00% | -20.00% | -33.33% | 25.00% | 50.00% | -20.00% |
Gross Margin | 53.46% | 50.52% | 53.82% | 50.15% | 49.30% | 44.29% |
Operating Margin | 23.71% | 16.83% | 22.65% | 19.09% | 17.25% | 11.02% |
Profit Margin | 20.89% | 12.65% | 17.54% | 15.55% | 14.27% | 10.23% |
Free Cash Flow Margin | 8.20% | 24.96% | 19.77% | 35.37% | 8.35% | 1.23% |
EBITDA | 12.75 | 7.95 | 10.17 | 10.53 | 9.94 | 5.95 |
EBITDA Margin | 27.03% | 19.95% | 25.65% | 22.83% | 21.50% | 16.34% |
D&A For EBITDA | 1.57 | 1.24 | 1.19 | 1.73 | 1.96 | 1.93 |
EBIT | 11.18 | 6.7 | 8.98 | 8.81 | 7.98 | 4.01 |
EBIT Margin | 23.71% | 16.83% | 22.65% | 19.09% | 17.25% | 11.02% |
Effective Tax Rate | 17.66% | 23.52% | 20.55% | 20.18% | 18.42% | 1.96% |
Advertising Expenses | - | 0.02 | 0.01 | 0.06 | 0.05 | 0.04 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.